Aytu BioPharma Files 10-Q, Details Warrant Exercises

TL;DR

Aytu BioPharma's 10-Q shows $6.1M assets, $6.0M liabilities, and exercised warrants at $0.0001.

AI Summary

Aytu BioPharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported $6,149,202 in total assets and $5,972,638 in total liabilities. The filing also details the exercise of 176,000 Tranche B Pre-Funded Warrants at a price of $0.0001 per share, which were previously classified as liabilities.

Why It Matters

This filing provides a snapshot of Aytu BioPharma's financial health and operational activities, including the impact of warrant exercises on its capital structure.

Risk Assessment

Risk Level: medium — The company's financial figures and the details of warrant exercises suggest potential financial complexities and ongoing operational adjustments.

Key Numbers

• $6.15B — Total Assets (As of September 30, 2024)
• $5.97B — Total Liabilities (As of September 30, 2024)
• $0.0001 — Warrant Exercise Price (For Tranche B Pre-Funded Warrants)

Key Players & Entities

• AYTU BIOPHARMA, INC (company) — Filer
• 20240930 (date) — Period of Report
• 20241113 (date) — Filed as of Date
• $6,149,202 (dollar_amount) — Total Assets
• $5,972,638 (dollar_amount) — Total Liabilities
• 176,000 (dollar_amount) — Number of Tranche B Pre-Funded Warrants exercised
• $0.0001 (dollar_amount) — Exercise price per share for warrants

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AYTU The Nasdaq Capital M

Filing Documents

• aytu20240930_10q.htm (10-Q) — 1206KB
• ex_722660.htm (EX-31.1) — 13KB
• ex_722661.htm (EX-31.2) — 13KB
• ex_722662.htm (EX-32.1) — 8KB
• aytu20231231_10qimg001.jpg (GRAPHIC) — 3KB
• 0001437749-24-034970.txt ( ) — 7956KB
• aytu-20240930.xsd (EX-101.SCH) — 78KB
• aytu-20240930_cal.xml (EX-101.CAL) — 67KB
• aytu-20240930_def.xml (EX-101.DEF) — 530KB
• aytu-20240930_lab.xml (EX-101.LAB) — 441KB
• aytu-20240930_pre.xml (EX-101.PRE) — 581KB
• aytu20240930_10q_htm.xml (XML) — 1308KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements 4 Unaudited Consolidated Balance Sheets 4 Unaudited Consolidated Statements of Operations 5 Unaudited Consolidated Statements of Stockholders' Equity 6 Unaudited Consolidated Statements of Cash Flows 7 Notes to the Unaudited Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 39

- OTHER INFORMATION

PART II - OTHER INFORMATION 40 Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 40 Item 5. Other Information 40 Item 6. Exhibits 40

SIGNATURES

SIGNATURES 41 2 Table of Contents CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This Report on Form 10Q ("Form 10-Q" or "this report") includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this report, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "potential," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation: our anticipated future cash position; the planned expanded commercialization of our products and the potential future commercialization of our product candidates; our anticipated future growth rates; anticipated sales increases; anticipated net revenue increases; amounts of certain future expenses and cost of sales; our plans to acquire additional assets or dispose of assets, anticipated increases or decreases to operating expenses, and selling, general, and administrative expenses; and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the risks described in "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10K for the year ended June 30, 2024 (" 2024 Form 10-K "), and in the reports we file with the United States Securities

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS AYTU BIOPHARMA, INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) September 30, June 30, 2024 2024 ASSETS Current assets: Cash and cash equivalents $ 20,108 $ 20,006 Accounts receivable, net 23,159 23,526 Inventories 11,739 12,141 Prepaid expenses and other current assets 5,732 5,097 Current assets of discontinued operations — 1,121 Total current assets 60,738 61,891 Non-current assets: Property and equipment, net 692 693 Operating lease right-of-use assets 1,225 829 Intangible assets, net 51,205 52,453 Other non-current assets 1,971 2,185 Non-current assets of discontinued operations — 44 Total non-current assets 55,093 56,204 Total assets $ 115,831 $ 118,095 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 13,513 $ 10,314 Accrued liabilities 33,723 38,143 Revolving credit facility 4,270 2,395 Current portion of debt 1,857 1,857 Other current liabilities 7,889 8,962 Current liabilities of discontinued operations — 557 Total current liabilities 61,252 62,228 Non-current liabilities: Debt, net of current portion 10,430 10,877 Derivative warrant liabilities 9,402 12,745 Other non-current liabilities 4,921 4,529 Total non-current liabilities 24,753 28,151 Commitments and contingencies (note 13) Stockholders' equity: Preferred stock, par value $.0001 ; 50,000,000 shares authorized; no shares issued or outstanding — — Common stock, par value $.0001 ; 200,000,000 shares authorized; 6,149,202 , and 5,972,638 shares issued and outstanding, respectively 1 1 Additional paid-in capital 348,324 347,688 Accumulated deficit ( 318,499 ) ( 319,973 ) Total stockholders' equity 29,826 27,716 Total liabilities and stockholders' equity $ 115,831 $ 118,095 The accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. 4 Table of Content

View Full Filing

View this 10-Q filing on SEC EDGAR